Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina

Journal of the American College of Cardiology

Volumn 36, Issue 1, 2000, Pages 25-31

  Webb, David J ^a   Muirhead, Gary J ^b   Wulff, Maria ^b   Sutton, J Andrew ^c   Levi, Roberto ^d   Dinsmore, Wallace W ^e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; NITRIC OXIDE DONOR; SILDENAFIL; VASODILATOR AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG POTENTIATION; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; STANDING; SYSTOLIC BLOOD PRESSURE; VERTIGO;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; AGED; ANGINA PECTORIS; BLOOD PRESSURE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; NITRIC OXIDE DONORS; NITROGLYCERIN; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0033927440     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00705-1     Document Type: Article

References (22)

1. Goldstein H., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
2. Jeremy J.Y., Ballard S.A., Naylor A.M., et al. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 79:1997;958-963.
3. Moreland R.B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. 62:1998;309-318.
4. Naylor A.M. Endogenous neurotransmitters mediating penile erection. Br J Urol. 81:1998;424-431.
5. Burnett A.L. Nitric oxide in the penis physiology and pathology . J Urol. 157:1997;320-324.
6. Ballard S.A., Gingell C.J., Tang K., et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 59:1998;2164-2171.
7. Boolell M., Allen M.J., Ballard S.A., et al. Sildenafil an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction . Int J Impot Res. 8:1996;47-52.
8. Kelly R.A., Balligand J.L., Smith T.W. Nitric oxide and cardiac function. Circ Res. 79:1996;363-380.
9. Umans J.G., Levi R. Nitric oxide in the regulation of blood flow and arterial pressure. Ann Rev Physiol. 57:1995;771-790.
10. Vallance P. Control of the human cardiovascular system by nitric oxide. J Hum Hypertens. 10:1996;377-381.
11. Haynes W.G., Noon J.P., Walker B.R., Webb D.J. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens. 11:1993;1375-1380.
12. Lamas S., Marsden P.A., Li G.K., et al. Endothelial nitric oxide synthase molecular cloning and characterization of a distinct constitutive enzyme isoform . Proc Nat Acad Sci USA. 89:1992;6348-6352.
13. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 329:1993;2002-2012.
14. Parker J.D., Parker J.O. Nitrate therapy for stable angina pectoris. N Engl J Med. 338:1998;520-531.
15. Collier J.G., Lorge R.E., Robinson B.F. Comparison of the effects of tolmesoxide (RX71107), diazoxide, hydralazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol. 5:1978;33-44.
16. Zusman R.M., Morales A., Glasser D.B., Osterloh I.H. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 83:1999;35C-44C.
17. Jackson G., Benjamin N., Jackson N., Allen M.J. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 83:1999;13C-20C.
18. Webb D.J., Freestone S., Allen M.J., Muirhead G.J. Sildenafil citrate and blood-pressure-lowering drugs results of drug interaction studies with an organic nitrate and a calcium antagonist . Am J Cardiol. 83:1999;21C-28C.
19. Waldman S.A., Murad F. Cyclic GMP synthesis and function. Pharmacol Rev. 39:1987;163-196.
20. Beavo J.A. Cyclic nucleotide phosphodiesterases functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
21. Morales A., Gingell C., Collins M., et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 10:1998;69-74.
22. Wallis R.M., Corbin J.D., Francis S.H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 83:1999;3C-12C.